Stockscreener 앱 받기
189.10
2.49%
4.60
시간 외 거래:
189.50
0.40
+0.21%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength? - Yahoo Finance
HC Wainwright Has Bullish Estimate for AXSM FY2026 Earnings - MarketBeat
Axsome begins phase III AXS-14 Forward trial for fibromyalgia management - MSN
Avoiding Lag: Real-Time Signals in (AXSM) Movement - Stock Traders Daily
Axsome Therapeutics stock hits all-time high at 184.45 USD By Investing.com - Investing.com India
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Axsome Therapeutics stock hits all-time high at 184.45 USD - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $260.00 at HC Wainwright - MarketBeat
Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Appears In Nasdaq Today CNS Discussions - Kalkine Media
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
Piper Sandler raises Axsome Therapeutics price target to $223 on growth outlook - Investing.com UK
Axsome Therapeutics begins phase 3 trial of AXS-14 for fibromyalgia - Investing.com Nigeria
Assessing Axsome Therapeutics (AXSM) After An 86% One-Year Share Price Surge - Sahm
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Axsome Therapeutics Initiates Forward Phase 3 Trial of AXS-14 for the Management of Fibromyalgia - marketscreener.com
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia - manilatimes.net
Axsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 for Fibromyalgia Management - Quiver Quantitative
Phase 3 test of AXS-14 for fibromyalgia begins at Axsome Therapeutics - Stock Titan
Cantor Fitzgerald reiterates Axsome stock rating, sees strategic potential By Investing.com - Investing.com UK
Axsome Therapeutics (AXSM) Price Target Increased by 13.75% to 207.38 - Nasdaq
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Axsome Therapeutics (BIT:1AXSM) Price Target Increased by 15.47% to 174.52 - Nasdaq
Risk Report: Is Axsome Therapeutics Inc stock trending bullishMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $190 to $225 - 富途牛牛
Baird raises Axsome Therapeutics stock price target to $209 on strong sales - Investing.com Canada
Is Axsome Therapeutics (AXSM) Pricing Reflect Long Term Growth After Pipeline Milestones And 90% Rally - Yahoo Finance
MoneyShow's Best Investment Ideas For 2026: Part 2 - Seeking Alpha
Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65% - Nasdaq
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue - The Manila Times
Iridian Asset Management LLC CT Has $10.15 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy - Chartmill
Axsome Therapeutics, Inc. $AXSM Shares Sold by Peregrine Capital Management LLC - MarketBeat
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
Discipline and Rules-Based Execution in AXSM Response - Stock Traders Daily
Why Axsome Therapeutics Inc. stock is rated strong buyMarket Sentiment Indicators & Maximize ROI With Proven Growth Stocks - bollywoodhelpline.com
Why Axsome Therapeutics Inc. stock could outperform in 20252025 Market Overview & Verified Chart Pattern Signals - ulpravda.ru
Will Axsome Therapeutics Inc. stock reach all time highs in 2025July 2025 Drop Watch & Daily Price Action Insights - Улправда
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out - Finviz
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - marketscreener.com
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equal-We - GuruFocus
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - MSN
5.17%
4.40%
자본화:
|
볼륨(24시간):